Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Pfizer's Bavencio combo nod sets up 3-way kidney cancer battle
Wednesday, May 15, 2019
The approval of Bavencio plus Inlyta in first-line kidney cancer puts Pfizer and Merck KGaA in a three-way battle for market share.
BMS arms itself for Opdivo-Keytruda fight in kidney cancer
Thursday, April 25, 2019
Bristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. BMS’ execs? Not so much.
Keytruda heaps pressure on Opdivo with kidney cancer debut
Monday, April 22, 2019
BMS investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble arrived two months early.
Between Merck and Pfizer, the race is on in kidney cancer
Tuesday, February 19, 2019
Two Big Pharmas are racing toward a new indication in kidney cancer, but thanks to new data from Merck, it may not matter who gets there first.
Big Keytruda win sets Merck up to steal BMS' kidney cancer share
Tuesday, February 12, 2019
BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
Exelixis takes Cabometyx into crowded liver cancer field
Tuesday, January 15, 2019
Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Former Aveo CFO found guilty of misleading investors
Wednesday, November 21, 2018
A federal jury ruled Aveo's ex-CFO David Johnston made untrue statements about tivozanib and that he made money as a result.
Roche yanks Tecentriq kidney cancer apps in U.S., EU
Tuesday, November 20, 2018
Roche’s I-O rivals are hurtling toward a showdown in kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.